Drug Profile


Alternative Names: Epitinib succinate; HMPL-813; Huposuan yipitini

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Oesophageal cancer

Most Recent Events

  • 02 Aug 2017 Hutchison Medipharma plans a phase I trial for Glioblastoma (NCT03231501)
  • 29 Nov 2016 Preliminary efficacy and safety data from a phase Ib trial in Solid tumours released by Hutchison MediPharma
  • 17 Aug 2016 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease) in China (PO) (Hutchison MediPharma pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top